SCHEMBL4020952

SCHEMBL4020952

Cc1c(F)cccc1C1C(C(=O)c2nccs2)CN(CC(=O)N(C)C)CC1C(=O)c1nccs1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EED O75530 2/20 0.37
KMT2A Q03164 2/20 0.35
CD274 Q9NZQ7 1/20 0.34
KDM4E B2RXH2 1/20 0.34
MGLL Q99685 3/20 0.34
CCNT1 O60563 2/20 0.33
CDK9 P50750 2/20 0.33
GRIN2B Q13224 3/20 0.33
RBP4 P02753 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C19 P33261 1/20 0.33
CASP3 P42574 1/20 0.33
SENP8 Q96LD8 1/20 0.33
SENP7 Q9BQF6 1/20 0.33
SENP6 Q9GZR1 1/20 0.33
HCRTR1 O43613 1/20 0.33
HCRTR2 O43614 1/20 0.33
GRM5 P41594 1/20 0.32
LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4020948 1.00 EED (0.37) EEDKMT2ACD274KDM4EMGLL
SCHEMBL4021790 0.90 KDM4E (0.39) KMT2ACD274KDM4EMGLLRBP4
SCHEMBL4021793 0.90 KDM4E (0.39) KMT2ACD274KDM4EMGLLRBP4
SCHEMBL4023704 0.88 KMT2A (0.37) KMT2ACD274KDM4EMGLLRBP4
SCHEMBL4023706 0.88 KMT2A (0.37) KMT2ACD274KDM4EMGLLRBP4
SCHEMBL4795618 0.86 EED (0.32) EEDKMT2AKDM4ELMNA
SCHEMBL4749426 0.86 EED (0.42) EEDCCNT1CDK9GRIN2BCYP2D6
SCHEMBL4749424 0.86 EED (0.42) EEDCCNT1CDK9GRIN2BCYP2D6
SCHEMBL4026176 0.85 KMT2A (0.39) KMT2ACD274KDM4EMGLLRBP4
SCHEMBL4023587 0.83 EED (0.41) EEDCD274CCNT1CDK9GRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070161674-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2007-07-12 US claimed
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US disclosed
US-20070161674-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2007-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161674-A1 Certain chemical entities, compositions, and methods TP53, VHL, RB1 EED 1022/4885KMT2A 2820/4885CD274 2530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.